title: Transgenic model for the discovery of novel human secretory non-pancreatic phospholipase A2 inhibitors.
abstract: Transgenic mice were created which overexpress human secretory non-pancreatic phospholipase A2 (sPLA2) pansomatically as a potential disease and drug-testing model. The mice were produced using a DNA construct in which the inducible mouse metallothionein gene promoter drives expression of a human sPLA2 minigene. High levels of sPLA2 were detected in several tissues by immunofluorescence localization. Expression in the testes caused hypospermia and male infertility. Circulating catalytically active sPLA2 could be induced to levels observed in patients undergoing a systemic inflammatory response but had no detectable effect on the mice. Therefore, these results suggest that sPLA2 hyperphospholipasemia alone may have only limited pathophysiological consequences. We further show that 3-[3-acetamide-1-benzyl-2-ethylindolyl-5-oxy]propane phosphonic acid LY311727), a potent new inhibitor of phospholipase A2 catalysis developed by our group, dramatically suppresses the circulating enzyme activity in these animals whereas 3-[3-acetamide-1-benzyl-2-propylindolyl-5-oxy]propane phosphonic acid (LY314024), a substantially less potent LY311727 analog, is without effect. These later results thus motivate the further development of this compound as a potential new therapeutic agent and valuable research tool.
authors.affiliation: Department of Cardiovascular Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.
authors.forename: N
authors.initials: N
authors.lastname: Fox
authors.forename: M
authors.initials: M
authors.lastname: Song
authors.forename: J
authors.initials: J
authors.lastname: Schrementi
authors.forename: J D
authors.initials: JD
authors.lastname: Sharp
authors.forename: D L
authors.initials: DL
authors.lastname: White
authors.forename: D W
authors.initials: DW
authors.lastname: Snyder
authors.forename: L W
authors.initials: LW
authors.lastname: Hartley
authors.forename: D G
authors.initials: DG
authors.lastname: Carlson
authors.forename: N J
authors.initials: NJ
authors.lastname: Bach
authors.forename: R D
authors.initials: RD
authors.lastname: Dillard
authors.forename: S E
authors.initials: SE
authors.lastname: Draheim
authors.forename: J L
authors.initials: JL
authors.lastname: Bobbitt
authors.forename: L
authors.initials: L
authors.lastname: Fisher
authors.forename: E D
authors.initials: ED
authors.lastname: Mihelich
mesh_terms: D000818:Animals; D015152:Blotting, Northern; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D010741:Phospholipases A / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics*; D054467:Phospholipases A2; D013737:Testis / Q000737:chemistry / Q000473:pathology
chemical_list: D004791:Enzyme Inhibitors; D007211:Indoles; C095553:LY 311727; D010741:Phospholipases A; D054467:Phospholipases A2